<DOC>
	<DOCNO>NCT01919294</DOCNO>
	<brief_summary>The main research question : In hypogonadal men non-alcoholic steatohepatitis ( NASH ) , Testosterone Replacement Therapy ( TRT ) , give 12 month 1. improve severity steatosis liver biopsy ( Primary Question ) ? 2. improve severity associate steatohepatitis liver biopsy ? 3. reduce liver fat content assess proton Magnetic Resonance Spectroscopy ( 1H-MRS ) ? The work propose open pilot study 10 patient , main aim ass effect size TRT regard end point ( regard publish data ) , thereby allow power calculation definitive phase II trial . Other aim would assess recruitment consent rate , would also inform design large study .</brief_summary>
	<brief_title>Testosterone Replacement Non-alcoholic Steatohepatitis ( TEREPINS )</brief_title>
	<detailed_description>20-35 % adult non-alcoholic fatty liver disease ( NAFLD ) , often lead liver inflammation damage sometimes cirrhosis , liver failure liver cancer ; common indication liver transplantation UK . No medical treatment show effective preventing progression . Some men NAFLD low serum level testosterone ( male hormone ) . Often , level slightly low cause symptom . However several reason think low level may aggravate liver disease . NAFLD think cause resistance tissue action hormone insulin ( Insulin Resistance IR ) . Low testosterone level may cause IR . Treatments prostatic cancer lower testosterone level result IR NAFLD . Mice produce testosterone also develop NAFLD reverse testosterone replacement . The investigator therefore speculate testosterone replacement men NAFLD low blood testosterone level reduce liver fat . Investigators study 10 men NAFLD inflammation scarring ( proven liver biopsy perform clinical diagnosis ) mildly reduce testosterone level . Investigators see give 12 month course Testosterone Replacement Therapy ( TRT ) men lessen severity liver damage . Consented patient see 6 , 18 , 30 , 42 52 week . Patients undergo baseline clinical assessment , blood test , ultra sound scan , magnetic resonance scan liver ( estimate liver fat ) , repeat liver biopsy end study . Patients complete questionnaire , undergo clinical assessment , blood test , ultrasound scan , magnetic resonance ( MR ) scan liver ( estimate liver fat ) baseline . Patients clinical assessment blood test 6-weekly interval 12 month . At 12 month patient repeat liver biopsy , ultrasound MR scan .</detailed_description>
	<mesh_term>Hypogonadism</mesh_term>
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<mesh_term>Testosterone undecanoate</mesh_term>
	<mesh_term>Testosterone</mesh_term>
	<mesh_term>Testosterone enanthate</mesh_term>
	<mesh_term>Testosterone 17 beta-cypionate</mesh_term>
	<mesh_term>Methyltestosterone</mesh_term>
	<criteria>Abnormal serum ALT &gt; 2 occasion least 3 month , despite standard lifestyle advice appropriate , regard moderation alcohol intake , weight reduction exercise . Negative serological test hepatitis Bs ag C antibody . Alcohol consumption &gt; 21 unit per week 2 week last year 3 month past 5 year , assess use lifetime alcohol consumption questionnaire . Liver biopsy , perform part clinical management within 6 month recruitment , show : ( ) steatosis ( Kleiner grade 2 3 ) ; ( b ) NASH ( combine intralobular inflammation hepatocyte ballooning score &gt; 1 ) ; ( c ) fibrosis Ishak stage &lt; 4 ; ( ) evidence suggest another major liver disease . Hypotestosteronaemia , define total serum testosterone &lt; 11 nmol/L . Investigators predict include 25 % men NAFLD define . Inability give inform consent . Age &lt; 18 &gt; 75 year . Symptomatic sexual dysfunction . Cirrhosis either baseline liver biopsy ( Ishak score 56 ) suggest presence varix , ultrasound ( small shrink liver , ascites , splenomegaly ) liver decompensation ( encephalopathy , abnormal serum direct bilirubin , albumin prothrombin time ) . Space occupy lesion ultrasound suspicion malignancy . Evidence chronic liver disease pace occupy lesion ultrasound suspicion malignancy . Prostatic nodule mass PR examination unless full urological examination rule prostate cancer Serum PSA alpha feta protein agespecific normal range Carcinoma male breast Taking medication ( amiodarone , antiretrovirals , sodium alproate , corticosteroid , tamoxifen ) previous 3 month ( know improve steatosis ) . Diabetes hyperlipidaemia , therapy change within last 12 month suboptimal control anticipate need change therapy study . Severe complicate obesity , likely require bariatric surgery next 2 year . LH/FSH level , raise possibility primary pituitary disease . Subject try hop conceive within next 18 month . Haematocrit &gt; 0.54 History following : Sleep apnoea , breast prostate liver cancer , congestive heart failure , chronic renal failure ( serum creatinine &gt; 150 ) , severe chronic obstructive airway disease , uncontrolled hypertension epilepsy depression migraine . Severe co morbidity likely opinion investigator reduce life expectancy &lt; 10 year . Hypersensitivity active agent excipients . On longterm warfarin heparinbased anticoagulant therapy . Treatment antiplatelet agent exclusion criterion , however , omit time liver biopsy , per normal clinical practice .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>nonalcoholic fatty liver disease</keyword>
	<keyword>nonalcoholic steatohepatitis</keyword>
	<keyword>hypogonadism</keyword>
	<keyword>testosterone replacement therapy</keyword>
</DOC>